H.C. Wainwright raised the firm’s price target on BridgeBio Oncology (BBOT) to $29 from $27 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT:
- BridgeBio Oncology initiated with a Buy at Stifel
- BridgeBio Oncology initiated with an Outperform at Raymond James
- BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley
- Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
- BridgeBio Oncology reports promising RAS and PI3Kα data